News & Blog
News & Blog
The Oxford-Harrington Rare Disease Centre Advances Discovery of Therapies for Friedreich’s Ataxia (FA)
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
Job Posting: Clinical Operations Manager
Meet the Community: Jamie Cusick
Meet the Community: Aly Bourbeau
December 2025 – Advocacy Newsletter
Meet the Community: Giovanna Boscolo Castilho Gonçalves
FA Community Conversations FA Cardiac Disease Webinar: Recording Available on YouTube
Meet the Community: Renee Brown